日本語 
Eisai Co., Ltd. DAYVIGO® (lemborexant) has been approved in China, where it’s sold as “达卫可®.” The drug will likely launch in the second quarter of fiscal year 2025. It’s for adults who have trouble falling asleep or staying asleep.
DAYVIGO is a dual orexin receptor antagonist. It targets the brain’s sleep-wake system by binding to orexin receptors OX1R and OX2R. It has a stronger effect on OX2R. This mechanism helps you fall asleep and stay asleep. It does this by reducing the drive for both REM and non-REM sleep.
The approval comes after global Phase 3 trials (SUNRISE 1 and 2) with about 2,000 adults. It also includes a Phase 3 study specific to China. Findings demonstrated the drug’s effectiveness in addressing insomnia symptoms.
Also Read: Lantern Pharma completes LP-300 Lung cancer trial signup
Insomnia is common in China. About half of adults struggle with it, as shown in the 2025 China Sleep Health Survey. Women and older adults are more affected. DAYVIGO is now approved in 22 countries, like Japan, the U.S., and Canada. Its launch in China shows a rising need for new treatments for sleep disorders.
English